A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/10/2019
Start Date:June 6, 2018
End Date:May 31, 2024
Contact:Reference Study ID Number: GO40311 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. and Canada)

Use our guide to learn which trials are right for you!

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

This study will evaluate the safety, tolerability, and pharmacokinetics of BTRC4017A in
participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2
(HER2)-expressing cancers.


Inclusion Criteria

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Life expectancy of at least 12 weeks

- Adequate hematologic and end-organ function

- Acute, clinically significant treatment-related toxicity from prior therapy must have
resolved to Grade
- Left Ventricular Ejection Fraction (LVEF) >/=50%

HER2-Expressing Breast Cancer-Specific Inclusion Criteria

- Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC

- Locally advanced or metastatic BC that has relapsed or is refractory to established
therapies

HER2-Expressing Gastric/Gastroesophageal (GEJ) Cancer-Specific Inclusion Criteria

- Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent
and/or metastatic disease, not amenable to curative therapy

- HER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testing

- HER2-positive gastric/GEJ cancer must have received prior trastuzumab, cisplatin (or
carboplatin or oxaliplatin or investigational platinum agent) and 5-fluorouracil
(5-FU)/capecitabine

HER2-Positive Solid Tumor Specific Inclusion Criteria

- HER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central)
laboratory testing

- Locally advanced, recurrent, or metastatic incurable malignancy that has progressed
after at least one available standard therapy; or for whom standard therapy has proven
to be ineffective or intolerable, or is considered inappropriate; or for whom a
clinical trial of an investigational agent is a recognized standard of care; or for
whom a clinical trial of an investigational agent is considered an acceptable
treatment option

Exclusion Criteria

- Pregnant or breastfeeding, or intending to become pregnant during the study or within
140 days after the last dose of BTRC4017A

- Significant cardiopulmonary dysfunction

- Known clinically significant liver disease

- Positive for acute or chronic Hepatitis B virus (HBV) infection

- Acute or chronic Hepatitis C virus (HCV) infection

- Human Immunodeficiency Virus (HIV) seropositivity

- Poorly controlled Type 2 diabetes mellitus

- History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias

- Current treatment with medications that are well known to prolong the Q-wave/T-wave
(QT) interval

- Known clinically significant liver disease

- Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active
CNS metastases (progressing or requiring corticosteroids for symptomatic control)

- Leptomeningeal disease

- Spinal cord compression that has not definitively treated with surgery and/or
radiation

- History of autoimmune disease

- Prior allogeneic stem cell or solid organ transplantation
We found this trial at
6
sites
New Haven, Connecticut 6520
(203) 432-4771
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Melbourne,
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
660 South Euclid Avenue
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials